XML 36 R25.htm IDEA: XBRL DOCUMENT v3.20.2
Research and Development Activity (Details Textual) - USD ($)
6 Months Ended 12 Months Ended
Oct. 03, 2017
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Research and Development Activity (Textual)        
Common stock issued (in shares)   10,897,630   10,770,948
Xencor, Inc. License Agreement [Member]        
Research and Development Activity (Textual)        
Non refundable fee $ 100,000      
Common stock issued (in shares) 1,585,000      
Common stock with fair value on discounted cash flow $ 12,221,000      
Common stock equal to fully diluted shares to purchase with fair value 10.00%      
Fair value of warrants $ 4,193,000      
Warrant exercise price based on valuation of the company $ 100,000,000      
Expiry date of warrants exercise price based on a valuation October 3, 2023      
Aggregate purchase price for exercise of option pro-rated for any partial exercise $ 10,000,000      
In-process research and development   $ 16,514,000    
Research and Development [Member]        
Research and Development Activity (Textual)        
GST reimbursements   24,392 $ 113,580  
Research and Development [Member] | UNITED KINGDOM        
Research and Development Activity (Textual)        
Research and development tax credit receivable   507,833   $ 395,850
VAT receivable   90,971   42,046
Reimbursements of research and development tax credit   0 152,514  
Research and Development [Member] | AUSTRALIA        
Research and Development Activity (Textual)        
Research and development tax credit receivable   537,010   172,289
Goods and services tax ("GST") receivable   64,029   $ 35,179
Reimbursements of research and development tax credit   0 0  
GST reimbursements   $ 45,266 $ 0